Nerlynx
What Nerlynx is used for
Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Nerlynx
- Active substance
- neratinib
- Disease area
- Breast Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01EH02
- Marketing authorisation holder
- Pierre Fabre Medicament
- Authorised in the EU since
- 2018
Official information
In the USA
Same active substance: Nerlynx
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Nerlynx used for?
Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy.
What is the active substance in Nerlynx?
Nerlynx contains neratinib.
Who makes Nerlynx?
The EU marketing authorisation holder is Pierre Fabre Medicament.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU